Management of infantile subglottic hemangioma: Acebutolol or propranolol? (original) (raw)
2010, International Journal of Pediatric Otorhinolaryngology
AI-generated Abstract
The management of infantile subglottic hemangiomas remains a clinical challenge due to potential airway obstruction and treatment side effects. This study compares the effectiveness and tolerability of acebutolol, a cardioselective beta-blocker with fewer side effects, to propranolol, a non-cardioselective beta-blocker commonly used for hemangioma treatment. Initial findings suggest acebutolol effectively controls hemangioma volume without adverse effects, proposing it as a preferable treatment option while recommending further randomized controlled studies to confirm these results.
Sign up for access to the world's latest research.
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Related papers
Management options for infantile subglottic hemangioma
American Journal of Otolaryngology, 1995
is a potentially lifethreatening lesion that was first reported in 1864 by MacKenzie.' The first description of subglottic hemangioma in an infant was made by Phillips and Ruh in 1912.2 Subglottic hemangiomas have a 2:l female to male preponderance and 80% to 89% present within the first 6 months of life.3'4 Presenting symptoms representing various degrees of airway distress include stridor, cough, cyanosis, hoarseness, dysphagia, emesis, and hemoptysis. Typically, these symptoms fluctuate with periods of remission. Cutaneous hemangiomas occur in 44% to 51% of these patients, and are often found in the head and neck area. Histopathologically, subglottic hemangiomas may be categorized as capillary, cavernous, and mixed type. The majority of subglottic hemangiomas are of the capillary type. Although the natural history of this lesion is unpredictable, the majority begin to involute and regress after 18 to 24 months of age. Various treatment modalities have been de-From the
A Life Threatening Subglottic and Mediastinal Hemangioma in an Infant
Journal of Craniofacial Surgery, 2019
tracheostomy or any other surgical intervention, and with no reported side effects. Propranolol is an effective, non-invasive treatment for life threatening infantile hemangiomas compressing the airway, should be used as a firstline treatment for subglottic hemangiomas when intervention is required.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.